Search - tctmd.com

Displaying 61 - 69 of 69

Sort: Relevancy | Date

Presentation TCT 2015

PAR-1 Antagonists and P2Y12 Inhibitors: What Are the Data and the Place of These Medications in the PAD Population (for Secondary Cardiovascular Prevention and PAD Itself)?

Presenter: Gary M. Ansel, Michael R. Jaff, Ori Ben-Yehuda

October 11, 2015

Presentation TCT 2014

Preloading P2Y12 Antagonists in NSTE-ACS and STEMI: Safe and Effective? What Regimens?

Presenter: Dominick J. Angiolillo

September 13, 2014

Presentation

Optimizing P2Y12-Receptor Inhibition in ACS Patients Based on Platelet Function Testing

Presenter: 228579|Daniel Aradi

January 29, 2014

Presentation TCT 2013

Rapid-Acting Potent IV P2Y12 Inhibition: Evolution or Revolution?

Presenter: Robert Harrington

October 27, 2013

Presentation TCT 2013

P2Y12 Reactivity units (PRU) to Predict Hyporesponsiveness to Clopidogrel in Patients with Chest Pain with Prior History of Coronary Artery Stenting in Emergency Department

Presenter: Rakesh Sharma, Stephen Erickson, Rohit Sharma, Hanumanth Reddy, Donald Voelker, Harvinder Dod, Vibhuti Singh, james Marsh

January 31, 2013

Presentation TCT 2012

Should P2Y12 Antagonists Be Continued Through CABG in Patients with ACS?

Presenter: Adnan Kastrati

October 24, 2012

Presentation TCT 2012

P2Y12 Inhibitors: Specific Agents for Specific Patient Cohorts? (STEMI, Diabetes, CKD, Prior Stroke, Etc.)

Presenter: Dirk Sibbing

October 22, 2012

Presentation TCT 2012

P2Y12 Inhibitors: Could Platelet Reactivity to Balance Between Bleeding and Ischemic Events

Presenter: Laurent Bonello

October 22, 2012

Presentation TCTAP 2012

P2Y12 Receptor Inhibitors: Which Drug and for Whom?

Presenter: Cheol Whan Lee

April 26, 2012

Advertisement

PAR-1 Antagonists and P2Y12 Inhibitors: What Are the Data and the Place of These Medications in the PAD Population (for Secondary Cardiovascular Prevention and PAD Itself)?

Preloading P2Y12 Antagonists in NSTE-ACS and STEMI: Safe and Effective? What Regimens?

Optimizing P2Y12-Receptor Inhibition in ACS Patients Based on Platelet Function Testing

Rapid-Acting Potent IV P2Y12 Inhibition: Evolution or Revolution?

P2Y12 Reactivity units (PRU) to Predict Hyporesponsiveness to Clopidogrel in Patients with Chest Pain with Prior History of Coronary Artery Stenting in Emergency Department

Should P2Y12 Antagonists Be Continued Through CABG in Patients with ACS?

P2Y12 Inhibitors: Specific Agents for Specific Patient Cohorts? (STEMI, Diabetes, CKD, Prior Stroke, Etc.)

P2Y12 Inhibitors: Could Platelet Reactivity to Balance Between Bleeding and Ischemic Events

P2Y12 Receptor Inhibitors: Which Drug and for Whom?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content